Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Katsuaki Tanaka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Masaaki Kondo(Yokohama City University Medical Center), Akitaka Shibuya, Juichi Takada(Kitasato University), Satoshi Morita(Kyoto University), Chiaki Okuse(St. Marianna University School of Medicine), Hisashi Hidaka(Kitasato University), Shinichi Ohkawa(National Cancer Center Hospital East), Masataka Taguri(Yokohama City University)
Hepatology Research
February 23, 2011
10.1111/j.1872-034x.2011.00778.x
Cited by 77

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632